The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) net income didn’t rise as precipitously, it did improve, gaining 2% to $1.39 billion. The latter figure shook out to $12.07 per share.
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday
view original post